skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: A Potent d-Protein Antagonist of VEGF-A is Nonimmunogenic, Metabolically Stable, and Longer-Circulating in Vivo

Abstract

Polypeptides composed entirely of d-amino acids and the achiral amino acid glycine (d-proteins) inherently have in vivo properties that are proposed to be near-optimal for a large molecule therapeutic agent. Specifically, d-proteins are resistant to degradation by proteases and are anticipated to be nonimmunogenic. Furthermore, d-proteins are manufactured chemically and can be engineered to have other desirable properties, such as improved stability, affinity, and pharmacokinetics. Thus, a well-designed d-protein therapeutic would likely have significant advantages over l-protein drugs. Toward the goal of developing d-protein therapeutics, we previously generated RFX001.D, a d-protein antagonist of natural vascular endothelial growth factor A (VEGF-A) that inhibited binding to its receptor. However, RFX001.D is unstable at physiological temperatures (Tm = 33 °C). Here, we describe RFX037.D, a variant of RFX001.D with extreme thermal stability (Tm > 95 °C), high affinity for VEGF-A (Kd = 6 nM), and improved receptor blocking. Comparison of the two enantiomeric forms of RFX037 revealed that the d-protein is more stable in mouse, monkey, and human plasma and has a longer half-life in vivo in mice. Significantly, RFX037.D was nonimmunogenic in mice, whereas the l-enantiomer generated a strong immune response. These results confirm the potential utility of synthetic d-proteins as alternativesmore » to therapeutic antibodies.« less

Authors:
 [1];  [2];  [2];  [3];  [4];  [5];  [5];  [1];  [6];  [2];  [1]
  1. Banting and Best Department of Medical Research and Department of Molecular Genetics, the Donnelly Centre, University of Toronto, Toronto, Ontario, Canada M5S 3E1
  2. Department of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, University of Chicago, Chicago, Illinois 60637, United States
  3. Pharmacokinetics &, Drug Metabolism, Amgen, Inc., Thousand Oaks, California 91320, United States
  4. Therapeutic Discovery, Amgen, Inc., Thousand Oaks, California 91320, United States
  5. Antibody Solutions, Sunnyvale, California 94089, United States
  6. Reflexion Pharmaceuticals, Inc., San Francisco, California 94104, United States
Publication Date:
Research Org.:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
USDOE Office of Science (SC), Basic Energy Sciences (BES)
OSTI Identifier:
1236725
Alternate Identifier(s):
OSTI ID: 1249238
Grant/Contract Number:  
AC02-06CH11357
Resource Type:
Journal Article: Published Article
Journal Name:
ACS Chemical Biology
Additional Journal Information:
Journal Name: ACS Chemical Biology Journal Volume: 11 Journal Issue: 4; Journal ID: ISSN 1554-8929
Publisher:
American Chemical Society (ACS)
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; immunology; peptides and proteins; rodent models; plasma; stability

Citation Formats

Uppalapati, Maruti, Lee, Dong Jun, Mandal, Kalyaneswar, Li, Hongyan, Miranda, Les P., Lowitz, Joshua, Kenney, John, Adams, Jarrett J., Ault-Riché, Dana, Kent, Stephen B. H., and Sidhu, Sachdev S. A Potent d-Protein Antagonist of VEGF-A is Nonimmunogenic, Metabolically Stable, and Longer-Circulating in Vivo. United States: N. p., 2016. Web. doi:10.1021/acschembio.5b01006.
Uppalapati, Maruti, Lee, Dong Jun, Mandal, Kalyaneswar, Li, Hongyan, Miranda, Les P., Lowitz, Joshua, Kenney, John, Adams, Jarrett J., Ault-Riché, Dana, Kent, Stephen B. H., & Sidhu, Sachdev S. A Potent d-Protein Antagonist of VEGF-A is Nonimmunogenic, Metabolically Stable, and Longer-Circulating in Vivo. United States. https://doi.org/10.1021/acschembio.5b01006
Uppalapati, Maruti, Lee, Dong Jun, Mandal, Kalyaneswar, Li, Hongyan, Miranda, Les P., Lowitz, Joshua, Kenney, John, Adams, Jarrett J., Ault-Riché, Dana, Kent, Stephen B. H., and Sidhu, Sachdev S. 2016. "A Potent d-Protein Antagonist of VEGF-A is Nonimmunogenic, Metabolically Stable, and Longer-Circulating in Vivo". United States. https://doi.org/10.1021/acschembio.5b01006.
@article{osti_1236725,
title = {A Potent d-Protein Antagonist of VEGF-A is Nonimmunogenic, Metabolically Stable, and Longer-Circulating in Vivo},
author = {Uppalapati, Maruti and Lee, Dong Jun and Mandal, Kalyaneswar and Li, Hongyan and Miranda, Les P. and Lowitz, Joshua and Kenney, John and Adams, Jarrett J. and Ault-Riché, Dana and Kent, Stephen B. H. and Sidhu, Sachdev S.},
abstractNote = {Polypeptides composed entirely of d-amino acids and the achiral amino acid glycine (d-proteins) inherently have in vivo properties that are proposed to be near-optimal for a large molecule therapeutic agent. Specifically, d-proteins are resistant to degradation by proteases and are anticipated to be nonimmunogenic. Furthermore, d-proteins are manufactured chemically and can be engineered to have other desirable properties, such as improved stability, affinity, and pharmacokinetics. Thus, a well-designed d-protein therapeutic would likely have significant advantages over l-protein drugs. Toward the goal of developing d-protein therapeutics, we previously generated RFX001.D, a d-protein antagonist of natural vascular endothelial growth factor A (VEGF-A) that inhibited binding to its receptor. However, RFX001.D is unstable at physiological temperatures (Tm = 33 °C). Here, we describe RFX037.D, a variant of RFX001.D with extreme thermal stability (Tm > 95 °C), high affinity for VEGF-A (Kd = 6 nM), and improved receptor blocking. Comparison of the two enantiomeric forms of RFX037 revealed that the d-protein is more stable in mouse, monkey, and human plasma and has a longer half-life in vivo in mice. Significantly, RFX037.D was nonimmunogenic in mice, whereas the l-enantiomer generated a strong immune response. These results confirm the potential utility of synthetic d-proteins as alternatives to therapeutic antibodies.},
doi = {10.1021/acschembio.5b01006},
url = {https://www.osti.gov/biblio/1236725}, journal = {ACS Chemical Biology},
issn = {1554-8929},
number = 4,
volume = 11,
place = {United States},
year = {Wed Feb 03 00:00:00 EST 2016},
month = {Wed Feb 03 00:00:00 EST 2016}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record at https://doi.org/10.1021/acschembio.5b01006

Citation Metrics:
Cited by: 62 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

Oral Treatment with the d -Enantiomeric Peptide D3 Improves the Pathology and Behavior of Alzheimer’s Disease Transgenic Mice
journal, August 2010


Mirror image phage display—a method to generate d-peptide ligands for use in diagnostic or therapeutical applications
journal, January 2009


A peptide's perspective on antigen presentation to the immune system
journal, November 2013


A comparison of the immunogenicity of a pair of enantiomeric proteins
journal, July 1993


Treatment with Aβ42 Binding D-Amino Acid Peptides Reduce Amyloid Deposition and Inflammation in APP/PS1 Double Transgenic Mice
book, January 2012


Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies
journal, July 1989


Engineered protein scaffolds as next-generation antibody therapeutics
journal, June 2009


Synthesis of proteins by native chemical ligation
journal, November 1994


Different roles of D‐amino acids in immune phenomena
journal, May 1997


Coot model-building tools for molecular graphics
journal, November 2004


Total Chemical Synthesis of Biologically Active Vascular Endothelial Growth Factor
journal, July 2011


D-peptides as immunogens and diagnostic reagents
journal, August 1998


PHENIX: a comprehensive Python-based system for macromolecular structure solution
journal, January 2010


Blocking of the PD-1/PD-L1 Interaction by a D -Peptide Antagonist for Cancer Immunotherapy
journal, August 2015


Inhibiting HIV-1 Entry
journal, October 1999


In situ neutralization in Boc-chemistry solid phase peptide synthesis: Rapid, high yield assembly of difficult sequences
journal, September 1992


An Ultrahigh Affinity d -Peptide Antagonist Of MDM2
journal, June 2012


Identification of D-Peptide Ligands Through Mirror-Image Phage Display
journal, March 1996


Chemical synthesis and X-ray structure of a heterochiral {D-protein antagonist plus vascular endothelial growth factor} protein complex by racemic crystallography
journal, August 2012


Mirror-image Phage Display: Aiming at the Mirror
journal, September 2003


Engineering novel binding proteins from nonimmunoglobulin domains
journal, October 2005


Mirror image proteins
journal, October 2014


Insights into the Mechanism and Catalysis of the Native Chemical Ligation Reaction
journal, May 2006


D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms
journal, July 2010


Design of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance
journal, August 2010


A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralizing antibodies
journal, November 1997


Antibodies for all: The case for genome-wide affinity reagents
journal, June 2012


Computational design of d-peptide inhibitors of hepatitis delta antigen dimerization
journal, November 2000


Thymus-Independence of Slowly Metabolized Immunogens
journal, September 1972


Potent D-peptide inhibitors of HIV-1 entry
journal, October 2007


Mirror image phage display – Generating stable therapeutically and diagnostically active peptides with biotechnological means
journal, October 2012


Studies on Synthetic Polypeptide Antigens
journal, July 1967


Phaser crystallographic software
journal, July 2007